{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T10:10:39Z","timestamp":1789726239441,"version":"4.0.1"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100023331","name":"LEO Pharma A\/S","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100023331","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s13555-026-01656-7","type":"journal-article","created":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T08:17:55Z","timestamp":1770279475000},"page":"2001-2018","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Long-Term Safety and Efficacy of Tralokinumab in Patients with Moderate-to-Severe Atopic Dermatitis Treated for up to 6\u00a0Years: Final Results from the Open-Label Extension Trial ECZTEND"],"prefix":"10.1007","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2633-985X","authenticated-orcid":false,"given":"Andrew","family":"Blauvelt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9963-8319","authenticated-orcid":false,"given":"H. Chih-Ho","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3498-2482","authenticated-orcid":false,"given":"Norito","family":"Katoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4730-2164","authenticated-orcid":false,"given":"Richard G.","family":"Langley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8860-0876","authenticated-orcid":false,"given":"Vivian","family":"Laquer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3318-729X","authenticated-orcid":false,"given":"Aleksandra","family":"Lesiak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1957-6600","authenticated-orcid":false,"given":"Ketty","family":"Peris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1139-0908","authenticated-orcid":false,"given":"Julien","family":"Seneschal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8532-6338","authenticated-orcid":false,"given":"Juan-Francisco","family":"Silvestre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2918-6481","authenticated-orcid":false,"given":"Richard B.","family":"Warren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0177-8722","authenticated-orcid":false,"given":"Andreas","family":"Wollenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8380-8114","authenticated-orcid":false,"given":"Matthew","family":"Zirwas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8718-6140","authenticated-orcid":false,"given":"Niels H\u00f8jsager","family":"Bennike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0227-4692","authenticated-orcid":false,"given":"Farzaneh","family":"Safavimanesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7185-7472","authenticated-orcid":false,"given":"Ann-Marie","family":"Tindberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5248-4332","authenticated-orcid":false,"given":"Kristian","family":"Reich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,5]]},"reference":[{"issue":"7","key":"1656_CR1","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1111\/jdv.15574","volume":"33","author":"JI Silverberg","year":"2019","unstructured":"Silverberg JI, Margolis DJ, Boguniewicz M, et\u00a0al. Distribution of atopic dermatitis lesions in United States adults. J Eur Acad Dermatol Venereol. 2019;33(7):1341\u20138.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1656_CR2","doi-asserted-by":"publisher","first-page":"2717","DOI":"10.1111\/jdv.16892","volume":"34","author":"A Wollenberg","year":"2020","unstructured":"Wollenberg A, Christen-Z\u00e4ch S, Taieb A, et\u00a0al. ETFAD\/EADV eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children. J Eur Acad Dermatol Venereol. 2020;34:2717\u20132744.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"1656_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.xjidi.2023.100214","volume":"3","author":"MAX Tollenaere","year":"2023","unstructured":"Tollenaere MAX, M\u00f8lck C, Henderson I, et\u00a0al. Tralokinumab effectively disrupts the IL-13\/IL-13R\u03b11\/IL-4R\u03b1 signaling complex but not the IL-13\/IL-13R\u03b12 complex. JID Innov. 2023;3(5):100214.","journal-title":"JID Innov"},{"issue":"11","key":"1656_CR4","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.1111\/all.15811","volume":"78","author":"EL Simpson","year":"2023","unstructured":"Simpson EL, Guttman-Yassky E, Eichenfield LF, et\u00a0al. Tralokinumab therapy for moderate-to-severe atopic dermatitis: clinical outcomes with targeted IL-13 inhibition. Allergy. 2023;78(11):2875\u201391.","journal-title":"Allergy"},{"issue":"4","key":"1656_CR5","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/j.jaad.2022.07.019","volume":"87","author":"A Blauvelt","year":"2022","unstructured":"Blauvelt A, Langley RG, Lacour J-P, et\u00a0al. Long-term 2-year safety and efficacy of tralokinumab in adults with moderate-to-severe atopic dermatitis: interim analysis of the ECZTEND open-label extension trial. J Am Acad Dermatol. 2022;87(4):815\u201324.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"1656_CR6","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1111\/bjd.19573","volume":"184","author":"JI Silverberg","year":"2021","unstructured":"Silverberg JI, Toth D, Bieber T, et\u00a0al. Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial. Br J Dermatol. 2021;184(3):450\u201363.","journal-title":"Br J Dermatol"},{"issue":"6","key":"1656_CR7","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1001\/jamadermatol.2023.0627","volume":"159","author":"AS Paller","year":"2023","unstructured":"Paller AS, Flohr C, Cork M, et\u00a0al. Efficacy and safety of tralokinumab in adolescents with moderate to severe atopic dermatitis: the phase 3 ECZTRA 6 randomized clinical trial. JAMA Dermatol. 2023;159(6):596\u2013605.","journal-title":"JAMA Dermatol"},{"issue":"3","key":"1656_CR8","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1111\/bjd.20832","volume":"186","author":"J Gutermuth","year":"2022","unstructured":"Gutermuth J, Pink AE, Worm M, et\u00a0al. Tralokinumab plus topical corticosteroids in adults with severe atopic dermatitis and inadequate response to or intolerance of ciclosporin A: a placebo-controlled, randomized, phase III clinical trial (ECZTRA 7). Br J Dermatol. 2022;186(3):440\u201352.","journal-title":"Br J Dermatol"},{"issue":"3","key":"1656_CR9","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1111\/bjd.19574","volume":"184","author":"A Wollenberg","year":"2021","unstructured":"Wollenberg A, Blauvelt A, Guttman-Yassky E, et\u00a0al. Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2). Br J Dermatol. 2021;184(3):437\u201349.","journal-title":"Br J Dermatol"},{"issue":"1","key":"1656_CR10","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.jaad.2021.03.032","volume":"85","author":"JF Merola","year":"2021","unstructured":"Merola JF, Bagel J, Almgren P, et\u00a0al. Tralokinumab does not impact vaccine-induced immune responses: results from a 30-week, randomized, placebo-controlled trial in adults with moderate-to-severe atopic dermatitis. J Am Acad Dermatol. 2021;85(1):71\u20138.","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"1656_CR11","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1001\/jamadermatol.2020.1948","volume":"156","author":"KE Mansfield","year":"2020","unstructured":"Mansfield KE, Schmidt SAJ, Darvalics B, et\u00a0al. Association between atopic eczema and cancer in England and Denmark. JAMA Dermatol. 2020;156(10):1086\u201397.","journal-title":"JAMA Dermatol"},{"issue":"1","key":"1656_CR12","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2024.2345739","volume":"35","author":"SR Feldman","year":"2024","unstructured":"Feldman SR, Guerin A, Gauthier-Loiselle M, et\u00a0al. Patient preferences for treatment attributes in moderate-to-severe atopic dermatitis: a discrete choice experiment. J Dermatolog Treat. 2024;35(1):2345739.","journal-title":"J Dermatolog Treat"},{"issue":"1","key":"1656_CR13","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2024.2308682","volume":"35","author":"ML Schaarschmidt","year":"2024","unstructured":"Schaarschmidt ML, Kromer D, Wellmann P, et\u00a0al. Patients\u2019 preferences for systemic treatment of atopic dermatitis: safety and efficacy count the most. J Dermatolog Treat. 2024;35(1):2308682.","journal-title":"J Dermatolog Treat"},{"key":"1656_CR14","doi-asserted-by":"crossref","unstructured":"Reich K, Langley RG, Silvestre-Salvador JF, et\u00a0al. Safety of tralokinumab in patients with moderate-to-severe atopic dermatitis followed for up to 4.5 years: an integrated analysis of 8 clinical trials. Br J Dermatol. 2025;ljaf309.","DOI":"10.1093\/bjd\/ljaf309"},{"issue":"6","key":"1656_CR15","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1111\/all.16108","volume":"79","author":"E Guttman-Yassky","year":"2024","unstructured":"Guttman-Yassky E, Kabashima K, Staumont-Salle D, et\u00a0al. Targeting IL-13 with tralokinumab normalizes type 2 inflammation in atopic dermatitis both early and at 2 years. Allergy. 2024;79(6):1560\u201372.","journal-title":"Allergy"},{"issue":"3","key":"1656_CR16","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1093\/bjd\/ljae439","volume":"192","author":"S Weidinger","year":"2025","unstructured":"Weidinger S, Bewley A, Hong HC, et\u00a0al. Predicting success with reduced dosing frequency of tralokinumab in patients with moderate-to-severe atopic dermatitis. Br J Dermatol. 2025;192(3):410\u20139.","journal-title":"Br J Dermatol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01656-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01656-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01656-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T03:38:03Z","timestamp":1775101083000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-026-01656-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,5]]},"references-count":16,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["1656"],"URL":"https:\/\/doi.org\/10.1007\/s13555-026-01656-7","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,5]]},"assertion":[{"value":"24 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"In the original article, revised version of supplementary material updated.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Andrew Blauvelt has served as a speaker (received honoraria) for Eli Lilly and Company, UCB, and Almirall; has served as a scientific adviser (received honoraria) for AbbVie, Almirall, Alumis, Amgen, Anaptysbio, Apogee, Arcutis, Astria, Boehringer Ingelheim, Bristol Myers Squibb, Celltrion, Corvus, Dermavant, Eli Lilly and Company, Galderma, GlaxoSmithKline, Immunovant, Incyte, IQVIA, Janssen, LEO Pharma, Lipidio, Merck, Novartis, Oruka, Paragon, Pfizer, Regeneron, Sanofi, Spherix Global Insights, Sun Pharma, Syncona, Takeda, UCB, Union, and Zai Lab; has acted as a clinical study investigator (institution has received clinical study funds) for AbbVie, Acelyrin, Almirall, Alumis, Amgen, Arcutis, Boehringer Ingelheim, Bristol-Myers Squibb, Dermavant, Eli Lilly and Company, Galderma, Incyte, Janssen, LEO Pharma, Merck, Novartis, Pfizer, Regeneron, Sanofi, Sun Pharma, Takeda, and UCB; and owns stock in Lipidio and Oruka. H. Chih-ho Hong is a researcher, consultant, and\/or advisor for AbbVie, Amgen, Arcutis, Aslan, Bausch Health, Boehringer Ingelheim, Bristol Meyers Squibb, Celgene, Dermavant, Dermira, DS Biopharma, Eli Litty, Evelo, Galderma, GlaxoSmithKline, Incyte, Janssen, LEO Pharma, MedImmune, Novartis, Organon, Pfizer, Regeneron, Roche, Sanofi Genzyme, Sun Pharma, and UCB. Norito Katoh has received honoraria as a speaker\/consultant for Sanofi, Maruho, Abbvie, Ely-Lilly Japan, Taiho Pharmaceutical, Pfizer, Mitsubishi Tanabe Pharma, Jansen Pharma, Kyowa Kirin, Celgene Japan, Torii Pharmaceutical, and Otsuka Pharmaceutical, and has received grants as an investigator from Mitsubishi Tanabe Pharma, Torii Pharmaceutical, Maruho, Sun Pharma, Boehringer Ingelheim Japan, Eisai, and LEO Pharma. Richard G Langley has served and received compensation in the form of grants and\/or honoraria as principal investigator for and is on the scientific advisory board or has served as a speaker for AbbVie, Amgen, Boehringer Ingelheim, Celgene, Eli Lilly, Janssen, LEO Pharma, Merck, Novartis, Pfizer, and UCB. Vivian Laquer has received grants from AbbVie, Eli Lilly, Galderma, LEO Pharma, and Novartis. Aleksandra Lesiak has participated in advisory boards and received speaker fees from Novartis, Lilly, Sanofi, Sandoz, Abbvie, Pierre Fabre, Alfa Sigma, Boehringer Ingelheim, and Pfizer. Additionally, she has served as a principal investigator for LEO Pharma, AnaptysBio, and Dermira, and received speaker fees from Galderma, UCB, and Janssen. Ketty Peris reports grants or personal fees for participation in advisory boards from AbbVie, Almirall, Galderma, Lilly, LEO Pharma, Novartis, Pierre Fabre, Sanofi, Sun Pharma, and Janssen. Julien Seneschal has served as an advisor, paid speaker, or participated in clinical trials (with honoraria paid to the institution) sponsored by: AbbVie, Almirall, Amgen, Bristol Myers Squibb, Eli Lilly, Galderma, Janssen-Cilag, LEO Pharma, Novartis, Pfizer, Pierre Fabre, Sanofi-Aventis, and UCB. Juan-Francisco Silvestre has served as a speaker, advisory board member, and\/or investigator for: AbbVie, Almirall, Amgen, Apogee, Astra Zeneca, Bristol Myers Squibb, Celldex, Eli Lilly, Galderma, Incyte, LEO Pharma, Novartis, Pfizer, Regeneron, and Sanofi Genzyme. Richard B. Warren has received research grants or consulting fees from AbbVie, Almirall, Amgen, Arena, Astellas, Avillion, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, DiCE, Eli Lilly, GSK, Janssen, LEO Pharma, Medac, Novartis, Pfizer, Sanofi, Sun Pharma, UCB, and UNION. He is supported by the Manchester NIHR Biomedical Research Centre. Andreas Wollenberg has served as an advisor, paid speaker, or participated in clinical trials (with honoraria paid to the institution) sponsored by: AbbVie, Aileens, Almirall, Amgen, Apogee, Beiersdorf, Bioderma, Bioproject, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Chugai, DKSH, Eli Lilly, Galapagos, Galderma, Glenmark, GSK, Hans Karrer, Hexal, Incyte, Janssen-Cilag, Kyowa Kirin, LEO Pharma, L\u2019Oreal, Maruho, MedImmune, MSD, Mylan, MSD, Nektar, Novartis, Pfizer, Pierre Fabre, Regeneron, Sandoz, Santen, Sanofi, and UCB. Matthew Zirwas has served as a speaker and\/or consultant and\/or investigator for Abbvie, Acrotech, Advanced Derm Solutions, Aldeyra, All Free Clear \/ Sun, Amgen, Anaptys Bio, Apogee, Arcutis, Basuch and Lomb, Beiersdorf, Biocon, Bristol Myers Squibb, Celldex, Cara Sun, Dermavant, Evommune, Evelo, Galderma, Google, Incyte, Janssen-Cilag, L\u2019Oreal, LEO Pharma, Eli Lilly, LUUM, Meta, Nimbus, Novan\u2019 Novartis, Pfizer, Q32 Bio, Regeneron, Sanofi, Supernus, Takeda, Trevi, Trifecta, UCB, and Verrica. Niels H\u00f8jsager Bennike, Farzaneh Safavimanesh, and Ann-Marie Tindberg are employees and\/or shareholders of LEO Pharma. Kristian Reich has served as advisor and\/or paid speaker for and\/or participated in clinical trials sponsored by Abbvie, Almirall, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Forward Pharma, Gilead, Galderma, Janssen-Cilag, Kyowa Kirin, LEO Pharma, Lilly, Medac, Novartis, Ocean Pharma, Pfizer, Sanofi, and UCB; Professor Reich is co-founder of Moonlake Immunotherapeutics.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The ECZTRA 1\u20138, TraSki, and ECZTEND trials were reviewed and approved by institutional review boards or ethics committees at each trial site and followed the Consolidated Standards of Reporting Trials guideline (Appendix in electronic Supplementary Material). The ECZTRA 1\u20138, TraSki, and ECZTEND trials were conducted in accordance with the ethical principles derived from international guidelines including the Declaration of Helsinki of 1964, and its later amendments, and Council for International Organizations of Medical Sciences International Ethical Guidelines, and in compliance with International Council for Harmonization guidelines for Good Clinical Practice. All participants provided written informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors thank the ECZTEND investigators and all individuals who participated in the ECZTRA 1\u20138, TraSki, and ECZTEND studies.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participants"}}]}}